Ventyx Biosciences (NASDAQ:VTYX) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Ventyx Biosciences (NASDAQ:VTYX) announced its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.13, Zacks reports.

Ventyx Biosciences Price Performance

VTYX opened at $1.45 on Friday. The stock has a market capitalization of $102.53 million, a PE ratio of -0.61 and a beta of 0.52. Ventyx Biosciences has a 12-month low of $1.44 and a 12-month high of $11.48. The firm’s fifty day moving average price is $1.98 and its 200 day moving average price is $2.15.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 21,119 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the transaction, the insider now directly owns 464,582 shares in the company, valued at approximately $1,096,413.52. The trade was a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Sheila Gujrathi purchased 130,000 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $2.31 per share, with a total value of $300,300.00. Following the purchase, the director now owns 130,000 shares of the company’s stock, valued at approximately $300,300. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 18.18% of the company’s stock.

Wall Street Analysts Forecast Growth

VTYX has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and issued a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.